PhoreMost and ThinkCyte have entered a strategic research partnership aimed at advancing modern phenotypic drug screening using artificial intelligence (AI). The partnership leverages both companies’ technologies in high-throughput drug discovery, PhoreMost’s phenotypic screening platform, SITESEEKER, and ThinkCyte’s AI-driven cell characterisation and sorting platform, Ghost Cytometry. Driven by advances in cell-based phenotypic screening tools and novel […]
